Polpharma Biologics Announces European Launch of the First Pre-Filled Syringe Biosimilar of Ranibizumab
Polpharma Biologics announced today that Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe) is now available for sale in France.
Ranivisio® is the first Lucentis® biosimilar offered in Europe in a convenient pre-filled syringe (PFS), setting a new benchmark for affordable biotherapies in ophthalmic care. This innovative configuration ensures accurate dosing and ease of use, promoting effective administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq.
The drug substance contained in Ranivisio® PFS is manufactured by Polpharma Biologics SA, a contract development and manufacturing organization (CDMO) operating under the brand name Rezon Bio, at its facilities in Poland. Rezon Bio is responsible for the commercial supply of the drug substance, ensuring consistent quality and reliability.
“The launch of Ranivisio® PFS in France is another important milestone in our mission to expand access to biologic medicines. With the first Lucentis® biosimilar available in a pre-filled syringe in Europe, we are setting a new standard in ophthalmic treatment. We are proud to support our partners in bringing an innovative, high-quality therapy to patients and healthcare professionals,” said Anjan Selz, CEO of Polpharma Biologics.
About Polpharma Biologics
Polpharma Biologics is a biopharmaceutical company that develops, manufactures, and commercializes biosimilars for global markets. We manage the entire value chain: from product selection and investment allocation to program implementation and asset monetization, to ensure rapid progression from idea to market. Our international team of experienced executives has recognized expertise in program management, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs, we offer end-to-end biosimilars—from cell line to finished product—in various major therapeutic areas. Our commercial partners ensure patients worldwide have access to these medicines. Our mission is to accelerate access to biotherapies. To achieve this, we maintain a robust and expanding pipeline of biosimilars in development.
The translated text of the press release should in no way be considered official. The only authoritative version of the press release is the one in its original language. The translation should always be compared with the source text, which will be the legal precedent.
